GLA
RPRX icon

Great Lakes Advisors’s Royalty Pharma RPRX Stock Holding History

Great Lakes Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$882K Buy
15,726
+4,253
+37% +$221K 0.01% 543
2026
Q1 		$550K Buy
11,473
+4,155
+57% +$182K ﹤0.01% 579
2025
Q4 		$283K Buy
7,318
+535
+8% +$20.4K ﹤0.01% 705
2025
Q3 		$239K Buy
6,783
+801
+13% +$29K ﹤0.01% 740
2025
Q2 		$216K Buy
+5,982
New +$198K ﹤0.01% 770

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Great Lakes Advisors's RPRX Position: Q2 2026 in Review

Great Lakes Advisors increased its Royalty Pharma (RPRX) stake by 37% in Q2 2026, buying an estimated $221K and bringing the position to 15,726 shares worth $882K. The position accounts for 0.01% of the portfolio, ranked #543.

Great Lakes Advisors first reported a position in RPRX in Q2 2025 and has held it in 5 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Great Lakes Advisors held 15,726 shares of Royalty Pharma worth $882K as of Q2 2026.
  • Great Lakes Advisors bought 4,253 Royalty Pharma shares in Q2 2026, an estimated $221K.
  • Royalty Pharma made up 0.01% of Great Lakes Advisors's portfolio in Q2 2026, its #543 holding.
  • Great Lakes Advisors first reported a position in Royalty Pharma in Q2 2025 and has held it in 5 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Great Lakes Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.